Ann Hematol: Heterogenetic stem cell transplantation is an effective treatment for DLBCL.

Heterogenetic hematopoietic stem cell transplantation (allo-SCT) is a potential treatment for patients with recurring or recurring large B-cell lymphoma (DLBCL).
, little information is available, especially for Japanese patients and cord blood transplants (CBTs).
study aims to determine the therapeutic effect of allogeneic SCT treatment for DLBCL in the Kyoto Stem Cell Transplant Group, a multi-agency joint research group.
included 68 DLBCL patients who received allogeneic SCT for the first time between 2003 and 2016.
from diagnosis to transplant has a medium time of 13.5 months.
31 patients were in CR/PR state at the time of the transplant.
27 patients were treated with CBT.
follow-up time for survivors was 44.2 months.
four-year total survival (OS) and resentment (RFS) rates were 23% (95% CI, 13-35%) and 20% (95% CI, 11-31%) respectively.
of non-recurrence mortality and recurrence were 23 per cent and 57 per cent, respectively.
patients who received allo-SCT had better OS (4 years, 46% vs 4%, P .lt;0.001) and RFS (4 years, 36% vs 7%, P s 0.005).
of stem cells did not significantly affect OS (4 years, bone marrow vs cord blood vs exosynamic blood, 28.6% vs 27.2% vs 6.5%, P s 0.193).
in multivariable analysis, the non-mitigation state of SCT is associated with poor OS and RFS.
the duration from diagnosis to transplantation is less than 1 year and is associated with poor RFS.
, the results suggest that Allo-SCT, including CBT, may be a promising treatment for patients with DLBCL who have good disease control at the time of transplantation.
.